# BALSIM Functional Work Package 2 — CLOSED

**SHARED CLINICAL CATALOGUE + COMPLETE EXPO CASE CONTENT — CLOSED**

**EXPO MEDICAL REVIEW GATE — CLOSED** under the owner-attested physician-review
contract below. This explicit owner-authorized checkpoint closes WP2; medical
approval alone did not automatically close the implementation work package.

Medical review: **COMPLETE — APPROVED_FOR_EXPO**
Approval basis: **OWNER_ATTESTED_PHYSICIAN_REVIEW**
Reviewer role: **PHYSICIAN**
Reviewer identity: **NOT_FORMALLY_RECORDED**
Exact physician review timestamp: **NOT_FORMALLY_RECORDED**
Owner attestation: **CONFIRMED**
Expo execution: **APPROVED_EXPO / ALLOWED**
Production publication: **PENDING / NOT_PUBLISHED**

The owner attests that a qualified physician reviewed both complete current
medical datasets and confirmed their correctness. This is not a verified
physician identity/signature, a fabricated review date, or a production approval.
No attestation timestamp is substituted for the unknown physician review time.

Current intended Expo packages are **Khalid 2.4.0 / Dana 1.5.0** with the same
`catalogue.balsim.expo-clinical@1.1.0` (33 concepts, 66 bindings).
Medical content is unchanged from the complete 2.3.0 / 1.4.0 datasets.
New immutable successors carry approved medical provenance and a trusted
version/hash/catalogue-bound owner-attestation envelope.

See [current approval contract and verification](../medical_review/OWNER_ATTESTED_EXPO_APPROVAL.md)
and [current completeness matrix](../medical_review/EXPO_CASE_COMPLETENESS_MATRIX.md).
Production publication, formal identity/time, media rights/matching, real RAG
sources and JU/JUST integration remain independent pending gates.
Closeout authorizes one scoped checkpoint commit, without push. WP3 is not started.
The closeout changes documentation only; it does not change medical content,
runtime contracts, prior versions, assets, or approval hashes. Existing passing
verification is retained; final checks cover package/hash/catalogue integrity,
review-pack consistency, secret/staging safety and whitespace.

## Preserved WP2 implementation and authoring history

The following earlier handoff is preserved as audit history. Its medical-pending
labels, old version pins and historical verification counts are not current
approval status. The current section above supersedes only medical approval
and intended Expo execution pins, not its clinical content or limitations.

# WP2 — Shared Clinical Catalogue / Explicit Case Outcomes

Status: **IMPLEMENTED — FINAL_EXPO_SCOPE**

**BALSIM_CASE_COMPLETENESS_READY_FOR_OWNER_REVIEW — YES** (authoring completed; physician/media review remains pending; WP2 not closed by this task)

Medical review: **PENDING_PHYSICIAN_REVIEW**

Baseline: `c57631b06ac193ac4522f91c44d770920cda9bf7`, `v2-development`.
Date: 2026-09-25. No commit/push; WP3 not started.

The earlier inspection found 40 Khalid actions, 28 Dana actions, 63 distinct IDs,
68 memberships, five shared observation IDs, and missing cross-case medication
outcomes. The owner's subsequent explicit authoring decision resolved that
planning-only blocker. This document supersedes the earlier blocked handoff.
Implementation approval is not physician, curriculum, media, or publication approval.
The 21-concept implementation below is the preserved v1.0.0 milestone, not current
case-completeness approval. The owner's correction requires expanded datasets and
explicit conflict review before WP2 may close.

## Current correction — catalogue 1.1.0

The current Expo host now uses Khalid 2.3.0 and Dana 1.4.0 with 33 identical shared
concepts: 14 investigations, 7 medication orders, 5 observations, 3 procedures,
3 supportive actions and 1 monitoring action. Eleven laboratory panels plus FoCUS
were added using explicit Case results, not runtime AI. Every shared concept is
bound in both Cases. Right ECG/tryptase are special search-only exceptions, not
first-level diagnosis hints. Results require a committed order and component
availability. Lab units/reference bands/qualifiers/sample/order/availability data
are displayed from safe server projections.

See [master completeness matrix](../medical_review/EXPO_CASE_COMPLETENESS_MATRIX.md)
and the two full physician-review packs linked there. The owner supplied Dana's
missing history/exam facts; they are now explicit pending-review authoring, not
inferred normal history/examination. Existing
discrepant numbers and tryptase behavior remain preserved, not overwritten by
the requested targets. Dana FoCUS is owner-supplied, pending review. Khalid's pain
remains persistent; post-reperfusion visuals are pending a separately authored
reperfusion state. The mismatched 84 bpm ECG image is not shown in the new successor.

### Prior correction verification — 2026-09-25

- **628 distinct affected Browser tests passed across the main run and targeted
  rechecks**. The main 622-test run exposed one legacy diagnostic fixture that
  lacked an order receipt/aligned clock. Its corrected fixture passed. Six added
  boundary tests also passed; current completeness file is **46/46**, current
  diagnostic API file **6/6**. Not a claim that the broad suite ran again unchanged.
- Result disclosure now requires a committed same-Session order and reached
  component-availability receipt. Session end does not bypass either gate.
  Inventory ignores foreign/future/unordered receipts. FoCUS prose is bounded
  at 4,000 characters while catalogue labels retain their shorter limit.
- **19/19 Deno**: successor exact hashes, WP1/WP2 parity, API/diagnostic/Case/
  Session/Clinical Engine, security and Patient Conversation.
- **12/12 Node** security/preflight checks passed; reused after no Node-runtime
  change in the final disclosure regression.
- **2/2 actual-App Playwright scenarios passed** on the final source tree:
  shared medication distractor, BP acquisition/reload, 14 investigation choices,
  parallel CBC/coagulation orders, delayed results with units/reference bands,
  preserved patient loading, and special-test search. Final captures wait for
  Visual Patient READY. No provider calls. Test-owned Windows hosts required
  stopping after successful scenarios/closed ports during teardown; no owner
  host was stopped. An earlier expanded run timed out and is not counted as PASS.
- Typecheck, build, portability and secret scan PASS. Existing bundle-size
  warning is non-blocking. Environment/key values were not read or printed.
- `git diff --check` PASS. Both full review packs match their read-only export
  from the current Case builders. Parent execution hashes remain asserted.
- Prior correction total WP2 WIP versus the WP1 baseline: **17 modified tracked + 23 new
  scoped files = 40 files** (includes the prior 26-file WP2 implementation).
  Nothing staged. Disposable failure screenshots moved recoverably to ignored
  `v2/test-results/wp2-completeness-disposable/`; review captures remain ignored.
- V1 hashes match; old medical packages, frozen Architecture/ADRs, patient media/
  assets, Voice/Conversation implementations and Visual Patient Lab unchanged.

Current actual-App evidence (local, ignored, no live providers):

- `v2/test-results/wp2-app/catalogue-Khalid-shared-ca-5363c-red-BP-and-existing-patient/Khalid-complete-labs.png`
- `v2/test-results/wp2-app/catalogue-Dana-shared-cata-1e5cc-red-BP-and-existing-patient/Dana-complete-labs.png`
- Same folders: `Khalid-special-search.png` and `Dana-special-search.png`.

**Previous content blocker resolved by owner decision:** Dana's chronic PMH,
regular medicines, family/social/substance history, pertinent negatives and all
eight baseline exam domains are now authored in successor 1.4.0. There are 18 new
patient-known history facts and 8 examiner-only facts; all carry hash-bound
SIMULATION_AUTHORED / PENDING_PHYSICIAN_REVIEW provenance in the existing Clinical
Facts module extension. No Case schema, engine, scoring or provider policy redesign.
No old fact was overwritten. Alcohol remains the supplied bounded wording rather
than inventing a frequency/quantity. Conflicting earlier laboratory targets remain
held as directed; see the matrix. No medical approval, WP2 closure, commit/push,
WP3 or final UI is claimed.

Dana 1.4.0 / `case-version.anaphylaxis.dana.005` execution:
`f468a31839af399b02b401aa5dde002d7ffc90d5da34026e3a8bb559a4084926`.
Review subject: `83324ccac70604a53c3f9df32c26b9c0f84a0bc4845bd82632d07b577a4a9f09`.
Dana 1.3.0 builder/hash and existing Session pins remain unchanged. New local
review boots use 1.4.0; existing hosts must restart to adopt it. Khalid 2.3.0
and its hash remain unchanged.

New Patient Conversation context contains only patient-known history additions.
All new exam facts retain `after_exam` and are explicitly forbidden to Patient
Conversation. The current visual framework selects a region/requests a clinical
action; it does not grant text findings. Expanded exam-action-to-findings delivery
is not added in this content pass. New examiner-only text remains withheld by
learner APIs; any later delivery must require a matching committed examination
and state-appropriate findings. WP1 numerical-vital acquisition is unchanged.

The sections below retain the v1.0.0 implementation evidence and prior hashes.
They are historical evidence, not the current dataset-completeness verdict.

### Owner-decision follow-up verification — 2026-09-25

- **352/352 Browser tests across 24 files PASS**, including 14 new Dana authoring,
  disclosure, successor preservation and state-transition checks; the 46 existing
  completeness checks; affected WP1/WP2, Patient Conversation, API, Case schema,
  security and Visual Patient regressions. This is a focused follow-up, not a
  second broad verification campaign or an additive count of unique tests.
- **12/12 Deno PASS**, including the new successor hash/history isolation check;
  **12/12 Node security/preflight PASS**.
- **2/2 actual-App Playwright scenarios PASS (exit 0)**. The current run explicitly
  asserts Khalid 2.3.0 and Dana 1.4.0 Session pins before checking shared actions,
  acquisitions, scheduling/results and the loaded patient. Evidence paths above
  now contain this run's captures. Test-owned Windows hosts were stopped after
  scenarios passed and their ports closed to complete teardown; no owner host
  was stopped. No external provider requests occurred.
- Typecheck, build, portability and secret scan PASS. The existing bundle-size
  warning is non-blocking. No credentials/environment values were read or printed.
- Final `git diff --check` PASS; all 26 scoped untracked files also pass the
  no-index whitespace check. Documentation-only closeout did not change tested code.
- Both complete physician-review packs match the current read-only Case export.
  The prior Dana 1.3.0 execution hash and Khalid 2.3.0 hash remain asserted.
- Current scoped WP2 WIP: **17 modified tracked + 26 new files = 43 files**;
  zero staged. This follow-up adds the Dana successor authoring file and two
  focused test files, plus review-pin/hash and handoff updates. Prior WP2 WIP
  remains intact. Local screenshots/test results remain ignored.
- Old medical packages, V1, patient assets, frozen Architecture/ADRs, Voice/
  Conversation implementations and Visual Patient Lab remain untouched.
- No physician approval, publication, commit, push, WP3 or final UI is claimed.

## Architecture — IMPLEMENTED

One public catalogue, **catalogue.balsim.expo-clinical@1.0.0**, is embedded identically
in two immutable REVIEW_ONLY successor packages. Internal exhaustive bindings map
neutral shared concept IDs to existing Case action IDs or explicitly authored
opposite-case actions. No destructive ID normalization.

The catalogue describes what exists: EN/AR labels, controlled aliases, categories,
fixed-order parameters, repeat/confirmation and visible prerequisite identities.
It contains no correctness, critical flag, score, diagnosis, effect, rubric or
Case-action binding. The API authorizes the Session and resolves the concept through
its pinned Case before using the existing authoritative command path.

Case-owned outcome policy includes source/rule references, explicit unmatched-rule
behavior, a modeling code, duration and pending review. No-benefit policies cannot
reference clinical rules, investigations or observation acquisition. Existing
Clinical Engine rules remain the only physiological/result authority. There is no
parallel engine. Receipts record the policy code/behavior/version and duration
internally; that classification describes the policy, not a claim that every
conditional rule fired. Effects and scheduled events remain authoritative evidence.

Source files:
- `v2/packages/contracts/src/clinical-catalogue.ts`
- `v2/packages/case-schema/src/shared-catalogue-validation.ts`
- `v2/content/cases/shared-catalogue/expo-catalogue.ts`
- `v2/content/cases/shared-catalogue/expo-cases.ts`
- Existing pinned-session, command, API, diagnostic renderer and equipment projection.

Single-action Interpreter reconciles shared concepts without execution. No compound
orders, external AI authoring, new prescribing engine or disclosure redesign.

## Scope and counts — EXPO_SUPPORTED

| Category | Concepts |
| --- | ---: |
| OBSERVATIONS | 5 |
| INVESTIGATIONS | 2 |
| MEDICATIONS | 7 |
| PROCEDURES | 3 |
| SUPPORTIVE_CARE | 3 |
| MONITORING | 1 |
| Total | **21** |

Seven fixed medication orders represent **six distinct drugs**: aspirin, ticagrelor,
clopidogrel, UFH, atorvastatin and epinephrine (first and repeat orders).
Procedures/support/monitoring total seven. Two investigations retain existing
authored results in both Cases. No normal result was inferred.

## Parameters, prerequisites, repeats and time

Selected parent medication actions are pre-authored fixed orders with no editable
parameters. Dose/route remain explicit in the common label and immutable binding;
requests adding arbitrary dose, route or effect fields fail. This is not an
arbitrary name-only prescription, weight calculator or alternative-dose engine.

New successors enforce IV before UFH and either fluid order. Repeat epinephrine
requires its first-dose action. Dana's five-minute eligibility/early-repeat rules
remain unchanged. There is one authored repeat-dose identity, not unlimited repeats.
Other selected non-observation actions remain NOT_REPEATABLE. Observations remain
repeatable; transport retries return the existing receipt, not a second execution.

Durations are **Expo compressed simulation fixtures**, not universal real-world
procedure times: medication orders 30 seconds; other orders 15 seconds; BP and
temperature/pulse/RR acquisition 30 seconds; pulse-ox 15 seconds. Existing monitoring
duration takes precedence (Khalid 15, Dana 30). The single Session time owner combines
trusted elapsed time and the authored duration once. Order time is not infusion
completion: the existing ten-minute saline response remains separately scheduled.

Valid non-beneficial orders commit, consume time and log evidence without a new
score weight or invented harm. Existing rubrics are unchanged. New distractor
scoring is a later policy decision, not invented here. Existing P2Y12 alternative
orders remain; no new cross-drug interaction model is claimed.

## Final Expo coverage matrix

Concepts below have prefix `concept.expo.`. **42/42 explicit bindings: 100%.**

A = inherited authored rules/result/acquisition/evidence, with an explicit bounded
no-modeled-benefit fallback when no conditional rule matches.
N = newly authored NO_MODELED_BENEFIT: time/evidence, no beneficial physiological
mutation and no invented harm/result. This is NOT universal pharmacological
inactivity, safety or prescribing advice.

K/D/W = existing Khalid/Dana/WP1 content; ACS = 2025 official ACS guidance;
RCUK = May 2021 emergency anaphylaxis guidance; AP23 = 2023 practice parameter;
M = owner-authorized bounded synthetic modeling decision.
PPR = PENDING_PHYSICIAN_REVIEW. All rows are technically Expo eligible, not approved medicine.

| Concept | Category | Khalid binding | Dana binding | Khalid outcome | Dana outcome | Parameters/prerequisites | Evidence | Physician review | Expo |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| bp | OBSERVATIONS | examination.observe.bp | examination.observe.bp | A: BP point/cuff | A: BP point/cuff | fixed, repeatable | W/M | PPR | YES |
| pulse | OBSERVATIONS | examination.observe.pulse | examination.observe.pulse | A: HR point | A: HR point | fixed, repeatable | W/M | PPR | YES |
| pulse-ox | OBSERVATIONS | examination.observe.pulse-ox | examination.observe.pulse-ox | A: SpO2 + HR points | A: SpO2 + HR points | fixed, repeatable | W/M | PPR | YES |
| respirations | OBSERVATIONS | examination.observe.respirations | examination.observe.respirations | A: RR point | A: RR point | fixed, repeatable | W/M | PPR | YES |
| temperature | OBSERVATIONS | examination.observe.temperature | examination.observe.temperature | A: temperature point | A: temperature point | fixed, repeatable | W/M | PPR | YES |
| ecg | INVESTIGATIONS | investigation.ecg-standard | investigation.dana.ecg | A: existing STEMI result | A: authored sinus tachycardia | fixed scheduled order | K/D/M | PPR | YES |
| cxr | INVESTIGATIONS | investigation.chest-xray | investigation.dana.cxr | A: existing authored CXR | A: authored no acute abnormality | fixed scheduled order | K/D/M | PPR | YES |
| aspirin | MEDICATIONS | medication.aspirin-324-chewed | medication.expo.aspirin-324-chewed | A: ACS order/rubric | N | 324 mg chewed | K/ACS/RCUK/AP23/M | PPR | YES |
| ticagrelor | MEDICATIONS | medication.ticagrelor-180 | medication.expo.ticagrelor-180 | A: ACS order/rubric | N | 180 mg oral | K/ACS/RCUK/AP23/M | PPR | YES |
| clopidogrel | MEDICATIONS | medication.clopidogrel-600 | medication.expo.clopidogrel-600 | A: alternative order/rubric | N | 600 mg oral | K/ACS/RCUK/AP23/M | PPR | YES |
| ufh | MEDICATIONS | medication.ufh-70-units-kg | medication.expo.ufh-70-units-kg | A: existing order/rubric | N | 70 units/kg IV; prior IV | K/ACS/RCUK/AP23/M | PPR | YES |
| atorvastatin | MEDICATIONS | medication.atorvastatin-80 | medication.expo.atorvastatin-80 | A: existing order/rubric | N | 80 mg oral | K/ACS/RCUK/AP23/M | PPR | YES |
| epinephrine | MEDICATIONS | medication.expo.epinephrine-im-05 | medication.dana.epinephrine-im-05 | N | A: epi flag/delayed response | 0.5 mg IM anterolateral thigh | D/ACS/RCUK/AP23/M | PPR | YES |
| repeat-epinephrine | MEDICATIONS | medication.expo.repeat-epinephrine-im-05 | medication.dana.repeat-epinephrine-im-05 | N | A: eligible/early-repeat evidence | 0.5 mg IM thigh; prior first dose | D/ACS/RCUK/AP23/M | PPR | YES |
| iv | PROCEDURES | procedure.peripheral-iv | procedure.dana.iv-access | A: access evidence/device | A: access flag/device | fixed | K/D/M | PPR | YES |
| saline-250 | PROCEDURES | procedure.normal-saline-250 | procedure.expo.normal-saline-250 | A: delayed authored support | N | 250 mL IV over 10 clinical min; prior IV | K/D/RCUK/M | PPR | YES |
| crystalloid-500 | PROCEDURES | procedure.expo.crystalloid-500 | procedure.dana.crystalloid-500 | N | A: delayed fluid response-ready | 500 mL IV bolus; prior IV | K/D/RCUK/M | PPR | YES |
| oxygen | SUPPORTIVE_CARE | procedure.supplemental-oxygen | procedure.dana.oxygen | A: existing support | A: existing oxygen flag | fixed authored support | K/D/RCUK/M | PPR | YES |
| help | SUPPORTIVE_CARE | consult.expo.call-help | consult.dana.call-help | N: receipt only | A: existing help evidence | fixed; no invented team response | K/D/RCUK/M | PPR | YES |
| cath | SUPPORTIVE_CARE | consult.activate-cath-lab | consult.expo.activate-cath-lab | A: existing activation evidence | N: receipt only | fixed; no invented procedure | K/D/ACS/M | PPR | YES |
| monitor | MONITORING | procedure.cardiac-monitor | procedure.dana.monitor | A: HR/rhythm continuous | A: HR/SpO2/rhythm continuous; BP point | fixed; Case-owned channels | W/K/D/M | PPR | YES |

## All twelve original medication actions inspected

| Original / home Case | Expo | Home outcome and opposite mapping |
| --- | --- | --- |
| medication.aspirin-324-chewed / Khalid | YES | Existing 324 mg order/rubric; Dana new N |
| medication.ticagrelor-180 / Khalid | YES | Existing 180 mg order/rubric; Dana new N |
| medication.clopidogrel-600 / Khalid | YES | Existing 600 mg alternative order/rubric; Dana new N |
| medication.ufh-70-units-kg / Khalid | YES | Existing IV order/rubric; both now require IV; Dana new N |
| medication.atorvastatin-80 / Khalid | YES | Existing 80 mg order/rubric; Dana new N |
| medication.nitroglycerin / Khalid | NO | Nitrate-harm rule preserved; unspecified dose, no Dana mapping authored |
| medication.iv-beta-blocker / Khalid | NO | Unsafe assessment evidence preserved; unspecified agent/dose, no Dana mapping |
| medication.norepinephrine-rescue / Khalid | NO | Incomplete rescue order/effect; no new infusion model |
| medication.dana.epinephrine-im-05 / Dana | YES | Existing first-line/delayed response; Khalid new N |
| medication.dana.repeat-epinephrine-im-05 / Dana | YES | Existing timing rules; Khalid new N |
| medication.dana.antihistamine-adjunct / Dana | NO | Adjunct consideration only; no fixed agent/dose; not elevated above epinephrine |
| medication.dana.bronchodilator-adjunct / Dana | NO | Adjunct consideration only; no fixed agent/dose or opposite mapping |

NOT_EXPO_ELIGIBLE exclusions are identical in both public catalogues. Original IDs
remain in inherited/old content for compatibility, not accessible through a raw-ID
bypass in these successor Sessions. Additional lab/echo/right-sided ECG/tryptase,
legacy exams and diagnosis/disposition choices lack both-Case shared coverage and
are not in this bounded public set. Larger catalogue/clinical model expansion is
DEFERRED_POST_EXPO; no case-specific filtering presents correct choices selectively.

## Investigations, devices and clinical preservation

Both ECG/CXR orders retain complete authored reports, results, timing and media.
Delays start at committed order time; scheduling remains independent and cannot
return early results. Dana media remains pending with deterministic text. Khalid
ECG/CXR remain REVIEW_ONLY/PENDING_PHYSICIAN_REVIEW; the library ECG 84 bpm vs Case
112 bpm discrepancy remains open. No Diagnostic Library source was changed/copied.
No unrelated investigation was assumed normal.

Numeric vitals remain unknown until acquisition; BP remains a point sample.
Only authored monitoring channels refresh continuously. BP cuff, IV access and IV
tubing remain downstream of committed actions. Both explicit fluid orders can show
existing tubing after access. PULSE_OX_VISUAL_ASSET_PENDING remains truthful.

Clinical facts, rules, dialogue, patient profile and rubric are compared exactly to
parents in tests. No new physiological harm or scoring weights. No asset changes.
Opposite-case fluid N policies describe a finite simulation without a partial/other
volume response model, NOT general claims about fluid efficacy. Physician review is
particularly important for these bounded choices.

## Source traceability / medical gate

See [EXPO_SHARED_CATALOGUE_REVIEW.md](../medical_review/EXPO_SHARED_CATALOGUE_REVIEW.md)
for all eleven new opposite-case outcomes and explicit inherited-policy handling.
Guideline reference metadata only is stored. New source records remain UNRESOLVED
and required: no copyrighted full document ingestion, RAG promotion or physician
approval. Both Cases remain UNDER_REVIEW/REVIEW_ONLY.

## Successor versions and immutable pins

| Case | Parent -> successor | Review execution hash |
| --- | --- | --- |
| Khalid | 2.1.0/.003 -> **2.2.0/.004** | bff79627aa2d99d6951cf3e4e325bab118772ad0b266b2e761ef61bd5cbe77ce |
| Dana | 1.1.0/.002 -> **1.2.0/.003** | 5fa47d6c2f00c2be192bcae9030dd861a502879f308ef1d74d1f5e224c79cc82 |

Review-subject hashes:
- Khalid: `823a813550d314eb356fdbc19c94d84c4d7a03f4eb9041073862983671b0d40d`
- Dana: `019275d96fb3496eb6357794e7ea6b84a04215141fb63c9b1f2012274ebd197f`

Parent execution hashes remain asserted:
- Khalid: `245d740fc945e684def834c5ec2e469170d3b3b6d7dbf176f341939e1010afa8`
- Dana: `46febaff5a13cdd8565922f3c65a48edd14a9ca1cd4b3d748996cb55a865eb2d`

Old Sessions retain old pins; no in-place package migration or source rewrite.
New action policies/prerequisites/durations are intentionally successor content.
Exact new execution hashes extend existing presentation compatibility only;
Visual Patient assets, V1, frozen Architecture, ADRs and Lab are untouched.

## Proof, security and verification

- 21 concepts and all learner labels/categories/parameters are byte-identical in both
  Cases. Availability does not disclose the Case; patient findings may still do so.
- All seven medication orders execute against each Case's explicit binding.
- Khalid aspirin / Dana epinephrine preserve appropriate authored behavior.
  Khalid epinephrine / Dana aspirin commit as bounded N distractors with 30 seconds
  and evidence, without invented physiology or public correctness.
- Opposite-case fluid distractors reject missing IV, then commit and show tubing
  without a fabricated clinical response. Eligible/early Dana repeat preserved.
- Two parallel investigations preserve no-early-result and pinned result mapping.
- Forged outcomes/parameters, foreign/raw IDs and foreign Session/result access
  fail closed. Adapter failure cannot leave partial time/devices/evidence.
- No external provider dependency. Interpreter proof uses a deterministic local
  provider double; no actual OpenAI or ElevenLabs request.
- **673 distinct affected Browser tests passed**: original 664 plus 9 added
  boundaries. Final WP2-only run: **44/44** across three files.
- **15/15 Deno**, including Browser/Deno exact shared catalogue/time/evidence parity.
- **12/12 Node** security/preflight checks.
- **2/2 actual-App Playwright scenarios**, exit 0. An initial singular-tab selector
  was corrected. After passing, two test-owned Windows host processes needed stop
  during teardown after their ports closed; no owner host was stopped.
- Typecheck and build PASS; existing bundle-size warning non-blocking.
- Portability PASS; false positive from the word "require" in a validator message
  corrected without altering the guard.
- git diff --check PASS. No broad full-suite or live-provider campaign.
- Secret scan PASS: repository text, built browser bundle and local text artifacts;
  environment not read and values not printed. V1 SHA-256 values match the baseline;
  frozen Architecture/ADRs, previous Case files, media/assets and Lab unchanged.
- Final scoped delta: 13 modified tracked files + 13 new files = 26 files;
  zero staged files. Earlier failed-test PNGs were moved recoverably into ignored
  test-results folders; no screenshots/recordings belong to the source delta.

## Actual App review access

From `C:/Projects/AI-Clinical-Simulation/v2`:
- `npm run dev:wp2` — Khalid loopback 4216.
- `npm run dev:wp2 -- --patient=dana` — Dana loopback 4217.
- Use each host's complete boot-generated Session URL.
- Existing secured local fixture boundary, fresh boot Session, memory-only
  persistence; no live-provider composition or credentials required.

Actual App proof: patient loaded, same seven medication orders, distractor HTTP 200,
BP unknown then acquired, reload preserves observation, temperature still unknown.
No final UI composition added. Review screenshots are ignored and not source:
- `v2/test-results/wp2-app/catalogue-Khalid-shared-ca-5363c-red-BP-and-existing-patient/Khalid-shared-medications.png`
- `v2/test-results/wp2-app/catalogue-Dana-shared-cata-1e5cc-red-BP-and-existing-patient/Dana-shared-medications.png`
- Same folders: `Khalid-wp2-observation.png` and `Dana-wp2-observation.png`.

Medical/media/source review remains separate and pending; no implementation blocker
remains. No commit, push, WP3, final mockups or clinical approval.
